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Significant advances in our understanding of neutrophil biology were made in the past
several years. The exciting discovery that neutrophils deploy neutrophil extracellular traps
(NETs) to catch pathogens paved the way for a series of additional studies to define the mol-
ecular mechanisms of NET generation and the biological significance of NETosis in acute
and chronic pathologic conditions. This review highlights the latest knowledge regarding
NET structures, deployment, and function, with an emphasis on current understanding of
NET proteomes, their conservation, and significance in the context of cystic fibrosis (CF), a
condition characterized by excessive extracellular DNA/NET presence.We also discuss how
our understanding of NETosis yields novel therapeutic approaches and their applicability
to CF.
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INTRODUCTION
The significance of the role of neutrophils in infection response has
been appreciated since the latter part of the nineteenth century. For
decades, it was understood that neutrophils primarily act in one of
two different ways upon activation: by releasing antimicrobial pro-
teins into extracellular space through degranulation, or through
phagocytosis of invading microbes. However, a recent focus,
spurred by the identification of neutrophil extracellular traps
(NETs), demonstrated yet another significant role for neutrophils
(1). NETs represent an innate immune response to bacteria, fungi,
and viruses (2). They have also been implicated in various patholo-
gies and are a significant area of study with the potential to create
novel therapies to a variety of immunological diseases.
NET CORE PROTEOME
Extracellular DNA serves as the physical scaffold upon which
the NET-associated proteins are attached to facilitate adhesion
and sequestration of pathogens, such as bacteria (3). The com-
ponents that comprise the highest proportion of NET protein
content are histones. Specifically, histones H2A, H2B, and H3 are
present in the high amounts of 379.3, 298.9, and 199.2 mg per
gram of NET DNA, which represents molar percentages of 26.29,
23.95, and 14.50%, respectively (2). The functional significance
of a substantial histone presence is that it represents a potential
attachment site for pathogens and carries antibacterial activity
(4). The remainder of proteins that decorates the NET DNA scaf-
fold include granular proteins, cytoplasmic proteins, cytoskeletal
proteins, and metabolic enzymes. They are present in far smaller
proportions. For example, myeloperoxidase (MPO) is present at
71.3 mg per gram of NET DNA, or a 1.01% molar amount (2).
Granular proteins include antimicrobial agents such as lactotrans-
ferrin and cathepsin G. Metabolic enzymes include alpha-enolase
and transketolase (2).
Neutrophil extracellular traps are released in response to var-
ious stimuli such as rheumatoid factor, IgG, TNF, or bacterial
pathogens, such as Pseudomonas aeruginosa (5–7). Although varia-
tions within the protein compositions of the NET proteomes were
reported, significant commonality was present in the repertoire
of the NETs deployed in response to various triggers. Nineteen
constituent proteins were consistently found in NET structures,
regardless of stimulus. These conserved proteins included β-
actin, α-actinin-1/4, α-enolase, filamin-A, histone H2A, histone
H2B, histone H4, lactoferrin, MPO, myosin-9, moesin, neutrophil
defensin 2, neutrophil elastase, neutrophil gelatinase-associated
lipocalin, plastin-2, profilin-1, resistin, glucoso-6-phosphate iso-
merase, and transketolase (Table 1) (6). Because of this conser-
vation of the repertoire, we propose to term this NET-associated
assembly the NET “core proteome”.
With regard to NET proteomic variations, it was reported that
rheumatoid factor elicited only six unique proteins, as did IgG,
and TNF yielded only three unique proteins (Table 1) (6). Across
the distinct stimuli, only 10–20% of decorative proteins were dis-
tinctive. The fact that proteomic variations existed was interpreted
as an indication that the various stimuli triggered different signal-
ing cascades that yielded the slightly varied results in proteomic
outputs. While this is certainly possible, another scenario is that
the additional decorative proteins adhered to NETs subsequently.
Given the highly adhesive nature of NETs, the structures likely
bound slightly different arrays of proteins in the different environ-
ments surrounding each stimulus. This view is consistent with the
role of NETosis as a component of the innate immune response,
which serves as a rapid defense that is not specifically tailored
to different pathogens. It is likely that differences in the protein
environment that surrounds NETs may lead to the differences in
the protein cargo that decorate them. Because of the significant
overlap in protein presence on the chromatin structures, we favor
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Table 1 | NET-reported proteomes.
Cellular Compartment NET-Constituent Protein PMA PA01 TNF RA IgG
Granules Leukocyte elastase + + + + +
Lactotrensferrin + + + + +
Azurocidin + + + − +
Cathepsin G + + + − +
MPO + + + + +
Leukocyte Proteinase + − − − +
Lysozyme + + + + −
Neutrophil Defensins + + − + +
Resistin − − + + +
Nucleus Histone H3 + + − − +
Histone H2B + + + + +
Histone H2A − + + + +
Histone H4 + + + − +
Enzymes α-enolase + + + + +
Transketolase + + + + +
GAPDH − + + + +
GPI − − + + +
Aldolase − + − − −
Cytoplasm Protein S100A9 + − + + +
Protein S100A8 + − + + +
Protein S100P − − + + +
Plastin-2 − − + + +
Filamin-A − − + + +
Peroxisome Catalase + + − + −
Cytoskeleton Actin (β/γ) + + + + +
Myosin-9 + + + + +
α-actinin (1/4) + + + + +
Profilin − − + + +
Moesin − + + + +
Membrane Neutrophil gelatinase-associated lipocalin − − + + +
Shared by three or more stimuli 18/19 19/20 25/25 23/24 26/27
Constituent NET proteins are indicated according to cellular localization. Proteins shared by three or more stimuli are italicized.
the concept that the NETs, when initially cast, carry a conserved
core proteome that is not dependent on the stimulus. Once in the
extracellular environment, NETs bind additional cargo.
The NET proteome provides insights into NET functionality,
in that constituent proteins can be categorized into functional
groups. For example, histones H2A, H2B, and H4, given the adhe-
sive nature of histones, serve to physically sequester pathogens
such as bacteria. Upon sequestration, microbial killing can be
executed through antimicrobial proteins, such as MPO, which gen-
erate cytotoxic reactive oxygen species (ROS) (HOCl), or through
nutritional immunity involving pathogen starvation of divalent
cations mediated by S100 proteins (2, 8). S100A8 and S100A9
starve Candida albicans via creating local environments with low
divalent ion concentrations, as divalent ion presence is required
for Candida albicans growth.
The aspect that needs further characterization is the clearance
mechanism that follows NETosis. It has been shown that serum
DNase I can clear NETs (9). However, whether serum DNase I
is systemically or locally upregulated with release of NETs, or
whether resident macrophages release DNase I to degrade NETs
remains to be explored. An enhanced understanding of the in vivo
clearance mechanism of NETs would be beneficial in the context
of pathologies that involve aberrant or excessive presence of extra-
cellular DNA or NETs. Of note, impaired NET homeostasis was
reported in SLE patients and is linked to decreased NET degrada-
tion likely due to deposition of anti-DNA antibodies onto NETs,
thereby shielding them from DNase I (10).
Interestingly, DNase I-mediated digest of NETs releases active
elastase (11). We speculate that this may contribute to the two-step
mechanism of NET bactericidal potential, which initially, upon
deployment, NETs capture, starves the pathogens, and, secondly,
upon partial degradation, releases a battery of antimicrobial pep-
tides to completely inactivate the target. This multi-step killing
mechanism is driven by the release of elastase, which preferentially
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targets histones, enolase, lactoferrin, etc. to generate antimicro-
bial peptides. Indeed, NETs are equipped with peptidyl prolyl
cis-trans isomerase, which is needed for the generation of active
histone-derived antimicrobial peptides.
MISSING LINKS IN OUR UNDERSTANDING OF HOW NETosis
OCCURS
Today, unlike 5 years ago, there is abundant information on stimuli
that induce NETosis. These include various pathogenic stimuli and
inflammatory mediators (e.g., TNF, IgG, TLR ligands, and com-
plement). For example, activation of Fc-receptors and associated
ITAMs can trigger NETosis (12).
However, we know relatively little about the intracellular events
resulting in the extracellular expulsion of chromatin. What we do
know is that, while not exclusively, to a large extent, NETosis is
a ROS-triggered event, dependent on the activity of NADPH oxi-
dase. This is true for a variety of pathogenic stimuli, including LPS,
TNF, and bacterial stimulation (e.g., P. aeruginosa) that lead to the
production of ROS through the enzymatic activity of NADPH
oxidase (7, 13).
A downstream event of NADPH oxidative activity is thought to
be peptidyl dearginase 4 (PAD4) activation (14). While the mol-
ecular details of the pathway remain unclear, it seems that the
release of ROS is translated into translocation of PAD4 to the
nucleus to modify histones H3 and H4 at Arg 17 and 3, respec-
tively, to convert them to citrulines and hence promote chromatin
decondensation (15); a latter step is needed for NET release. This
also results in a loss of the characteristically multilobular mor-
phology of the neutrophil nucleus, as demonstrated by electron
microscopy of neutrophils upon PAD4 activation (16). To work,
PAD4 requires high levels of calcium (17). This requirement of
PAD4 is difficult to reconcile with the concentrations of calcium
in the cell. So, how does the PAD4 work? It is possible that PAD4
forms complexes with yet unidentified protein partners that lower
the requirement of PAD4 for calcium. This scenario is based on
the example that PAD4, complexed with antibody, displays lower
need for calcium (18). Another possibility is that increased cal-
cium levels result from activation of ITAMs, and such elevated
levels of calcium promote the activation of PAD4 (19). Alterna-
tively, compromises in plasma membrane integrity might facilitate
extracellular calcium influx, thereby promoting PAD4 activation,
consistent with the original model that NETosis is a form of cell
death, given that a certain threshold of activation is met. Yet, this
concept has been challenged by the observation that after NET
release, cells retain mobility (20, 21).
Neutrophils rely heavily on glycolysis and the pentose phos-
phate cycle for generating ATP and NADPH. The presence of meta-
bolic enzymes on NETs suggests a possible link between metabolic
state and NETosis. It is likely that decrease in the influx of glu-
cose slows down glycolysis and triggers compensatory responses
such as autophagy activation. Expectedly, there is a link between
cellular autophagy and NETosis. Mammalian target of rapamycin
(mTOR) regulates NET formation by post-transcriptional control
of hypoxia-inducible factor 1α (HIF-1α) in response to LPS (22).
Autophagy leads to chromatin decondensation, which precedes
NET release (23). Furthermore, a separate study revealed that
inhibitors of PAD4 produced a reduction in autophagy activities
in an osteocarcinoma cell line (24). Clearly, a positive correlation
between the two processes exists.
Infection may lead to nutrient depravation, which is an induc-
ing factor of autophagy (25) Alterations in concentrations of
substrate, such as the nutrient glucose, for glycolysis, or the pen-
tose phosphate cycle, is paralleled by alterations in secondary
modifications of metabolic enzymes and their locations within
the cell. This model comes from the activation mechanisms of
the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). GAPDH is of particular interest, as it has been shown to
be consistently present on NETs (Table 1) (6). It has been recently
elucidated that, upon stress conditions on the cell, GAPDH is
translocated from the cytoplasm to the nucleus (26). This translo-
cation occurs as a result of post-translational modifications on the
GAPDH molecule. For example, activation of Fc-receptors can
trigger ROS production (27). This ROS presence, in turn, yields
modifications, through metabolic changes, of GAPDH, including
acetylation and nitrosylation, which facilitate its transfer to the
nucleus. This model is a reflection of GAPDH forming complexes
with nuclear chromatin that is subsequently expelled from the
nucleus and the cell upon histone citrullination by PAD4. The
question that is raised by the GAPDH model of metabolism-
linked translocation to the nucleus is whether PAD4 translocation
to the nucleus may follow the same model and be influenced by
metabolic state. This notion will need to be studied in order to
determine if an intimate link between metabolic stress and PAD4
activation and subsequent NETosis exists.
DOES OUR CURRENT KNOWLEDGE OF NETosis SUGGEST
NEW TREATMENT OPTIONS FOR CYSTIC FIBROSIS?
Elevated presence of extracellular DNA is a hallmark of cystic
fibrosis (CF), and it is natural to question what proportion, if
any, of the extracellular DNA is extracellular trap (ET)-derived.
Traditionally, extracellular DNA has been viewed as originating
from cellular debris. Indeed, administration of rhDNase (e.g.,
pulmozyme) does lead to a reduction in the concentration and
length of extracellular DNA and is used in clinic for treatment
of CF (28). Clues that the extracellular DNA in CF might be ET-
derived are emerging from recent studies. Dubios and colleagues
produced beautiful images of the characteristic morphological
hallmarks of NETosis in neutrophils (loss of lobular nucleus,
breakage of nuclear envelope, and decondensation of chromatin)
in a patient with CF; unfortunately, quantification of the data was
missing (29). Another study, conducted by Papayannopoulos and
colleagues, utilized native-PAGE analysis to characterize the chro-
matin structures in CF sputum samples from 10 CF patients who
were not on DNase I therapy. Authors reported that complexes
between extracellular DNA, neutrophil elastase, and MPO existed
in CF sputum, and that solubilization of sputum depended on
NET-released elastase that proteolytically targeted NET-associated
histones (11). Authors suggested that as much as 50% of the extra-
cellular DNA in the CF sputum might be NETs; however, while this
data was quite exciting, the study provided no patient information.
Using LC-MS/MS analysis of NET-enriched samples derived from
a cohort of CF patients we showed a significant conservation of
NET-associated proteins, again suggesting that NETs were present
in CF (5). Clearly, further research is warranted to quantify the
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ET structures in CF and correlate their presence with disease pro-
gression. The existence of conserved NET-associated protein cargo
[e.g., NET-associated elastase, MPO (7), α-enolase, or transketo-
lase] makes such a study feasible. While it appears highly likely
that the majority of the eDNA is ET-derived, this will pinpoint
to an exacerbated innate immune response that fails to target the
bacterial colonizer while allowing for the inflammatory milieu that
might support the very pathoadaptation of bacteria that represents
a partial cause of the etiology of CF symptoms.
A direct consequence of the absence of the CFTR channel is
the alteration of the ion balance in extracellular secretions. Cal-
cium metabolism disorder is central to this pathology. CF patients
present with significantly elevated concentrations of Ca2+ lev-
els in pulmonary fluid and nasal secretions (30, 31). Given the
dependence of NETosis on Ca2+, it is tempting to speculate that
neutrophils in the CF lung environment may tend to NETose more
readily compared to neutrophils in the non-CF environment.
Cystic fibrosis patients are predominantly colonized with P.
aeruginosa species. It is thought that this occurs due to the
impaired mucocilliary transport that allows for the establishment
of chronic bacterial infection in the absence of mechanical clear-
ance. What this scenario does not account for is why there is
species-specific dominance. The answer to this question, albeit
difficult, was previously sought (32), but multiple scenarios that
are not mutually exclusive are possible. A scenario that currently
intrigues us is that pathogen sequestration by NET structures
promotes bacterial microcolonization, and, as mechanical clear-
ance of these microcolonies fails in CF, the NETosing neutrophils
drive bacterial pathoadaptation, thereby having the innate immu-
nity govern colonization. The Pseudomonas dominance can be
explained by its incredible pathoadaptability to withstand the bac-
tericidal activities of NETs. Data from our group suggest that the
non-mucoid P. aeruginosa were more efficiently trapped by NETs
than the mucoid strains (5, 33). In addition, the non-mucoid
strains induced NET formation better than the mucoid strains.
Several Pseudomonas-derived factors were implicated including
flagella and pyocyanin (5, 34). In the case of CF, such NET
release may actually support initial bacterial sequestration and
drive mutability. Indeed, NETs are equipped with proteins that
were implicated in P. aeruginosa mutagenesis. A recent insight-
ful research report shows that LL-37, a component of NETs,
triggers P. aeruginosa mutagenesis (35). Sub-inhibitory concen-
trations of LL-37 induced mutations within the mucA gene to
promote antibiotic resistance. Together, these findings highlight
potential deficiencies in the NET model of defense, particularly in
the context of chronic CF infection, and demonstrate the need to
therapeutically address the presence of NETs in CF (Figure 1).
One popular symptomatic treatment option for CF is
the administration of recombinant human DNase I (rhD-
NAse/pulmozyme/dornase alfa) (36) in order to clear the abnor-
mally high levels of eDNA present (11). Clinical evidence shows
that treatment with Dornase alfa over a limited period of
time ranging from 1 up to 2 years is associated with moderate
improvement of lung function. The majority of the Dornase alfa
trials include patients whose age range from young children to
adults. This makes it difficult to asses whether there is a specific
window for treatment where the administration of rhDNase I is
most beneficial to patients. If NETs provide a scaffold for bacterial
retention, and, hence, promote bacterial colonization, then early
treatment with rhDNAse may be more beneficial than late.
Given our current understanding of NET biology, concern
exists with regard to the use of DNase I. This is especially raised
due to the propensity of DNase I to release NET-resident elas-
tase, which subsequently degrades histones (11). Since histones are
NET components that contribute to bacterial adhesion (and there-
fore sequestration), a decrease in histones may yield a decrease
in bacterial sequestration. This is especially significant if bacteria
were not effectively killed by NETs in CF, as, in that case, DNase I
therapy may, in part, be contributing to the release of pathogenic
bacteria and the concomitant exacerbation of infection. One way
to address this complication would be to administer an elastase
inhibitor along with DNase I; another way would be to reduce the
NETosis process altogether by inhibiting an upstream component.
There are approaches and candidate drugs to decrease NETosis. For
example, chloroquine, an anti-malarial drug, inhibits in vitro gen-
eration of NETs. Alternatively, PAD4 inhibitors similarly decrease
NETosis. Another potential approach to controlling NET release
is to engage the Siglec 9 neutrophil surface receptor. Siglecs are
a family of immunoglobulin-like cell receptors, of which many
have inhibitory cytosolic motif components (ITIMs). Siglec 9 is
one such receptor known to have this ITIM element. Once the
extracellular domain of Siglec 9 binds with an α2–3 sialic acid
linkage of a sialoglycoprotein near the neutrophil cell, the ITIM
element signals tyrosine phosphorylation and upregulation of
SHP-1 and SHP-2, which leads to secretion of anti-inflammatory
cytokines, including IL-10 (37). Perhaps a small molecule, such as a
sialated microcarrier or antibody, may allow for Siglec 9-mediated
inhibition of NETosis in a more controlled manner. Neither of
these options has been currently tested in the CF animal models;
however, they may hold promise.
While, initially, NETs are casted to carry a conserved core of
associated proteins, what gets deposited on the NET structures
defines the outcomes of NET-mediated inflammatory regulation.
In SLE, the excessive deposition of IgG onto NETs reduces accessi-
bility of the DNase 1 and,consequently, the timely removal of NETs
is impaired, contributing to attendant autoimmune responses. Do
NET reservoirs induce autoantibodies in CF? Would the coating
of NET fragments in CF with antibodies and complement impair
their clearance similarly to SLE? No studies have been undertaken
to define the levels of anti-DNA or anti-histone antibody titers
in CF so far. However, our initial data suggests that complement
C3b is highly deposited on CF-patient derived NET structures,
supporting this possible scenario.
In gout, aggregated NET structures carry serine protease
enzymatic activities that degrade the proinflammatory cytokines
deposited on the NETs, while sparing the NET-associated IL-8
and IL-1RA and, thereby, promote resolution of inflammation
(38). This exciting discovery illustrated that, depending on the
concentration and composition, NETs stimulate quite a variety
of inflammatory responses. Shauer and colleagues suggested that
impairment in aggNET formation leads to chronic inflammation.
It is tempting to question whether CF-specific NET composi-
tion exists to alter the inflammatory milieu and cause chronic
inflammation and impaired bacterial clearance. Unfortunately,
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FIGURE 1 | Proposed scenario for NET-triggered P. aeruginosa
pathoadaptation. NETosis is stimulated by P. aeruginosa-derived
virulence factors released by the non-mucoid “early” strains. The
generation of NETs requires activation of NADPH oxidase and ROS
production. NETs (blue) provide a scaffold for bacterial attachment and
microcolony formation. Albeit sequestering bacteria, NETs fail to
successfully kill Pseudomonas sp. Only a few dead bacteria (red) are
present within the NET-attached microcolonies. The sublytic
concentrations of the anti-microbial NET-associated proteins trigger
P. aeruginosa adaptation and stimulate acquisition of mutations that are
associated with polysaccharide production and antibiotic resistance.
Consequently, P. aeruginosa acquires mucoid phenotype (green bacteria
embedded in light green polysaccharide). The mucoid P. aeruginosa strains
trigger less NETosis due to decreased expression of virulence factors, and
may escape from NET trapping by elevated outer membrane vesicle
production and DNA shedding.
reports on CF-NET composition during disease exacerbations
are limited.
CONCLUDING REMARKS
Although NETs carry a formidable collection of weaponry to
sequester and impair the spread of bacteria, they fare better at
trapping than killing. NET-mediated immunity relies on mechan-
ical clearance from the mucosal surfaces, and, when this fails, in
cases such as CF, NETs may drive bacterial microcolonization. In
this sense, the use of DNase I, once bacteria have colonized the
lungs, will not be as efficient as when administered much earlier to
prevent colonization. Alternatively, novel approaches to regulate
NETosis should be discovered to limit excessive eDNA presence
and the ensuing inflammatory responses.
REFERENCES
1. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al.
Neutrophil extracellular traps kill bacteria. Science (2004) 303(5663):1532–5.
doi:10.1126/science.1092385
2. Urban CF, Ermert D, Schmid M, Abu-Abed U, Goosmann C, Nacken W, et al.
Neutrophil extracellular traps contain calprotectin, a cytosolic protein com-
plex involved in host defense against Candida albicans. PLoS Pathog (2009)
5(10):e1000639. doi:10.1371/journal.ppat.1000639
3. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, et al. Platelet
TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood.
Nat Med (2007) 13(4):463–9. doi:10.1038/nm1565
4. Chaput C, Spindler E, Gill RT, Zychlinsky A. O-antigen protects gram-negative
bacteria from histone killing. PLoS One (2013) 8(8):e71097. doi:10.1371/
journal.pone.0071097
5. Dwyer M, Shan Q, D’Ortona S, Maurer R, Mitchell R, Olesen H, et al. Cystic
fibrosis sputum DNA has NETosis characteristics and neutrophil extracellular
trap release is regulated by macrophage migration-inhibitory factor. J Innate
Immun (2014). doi:10.1159/000363242
6. Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi
S, Knight JS, et al. NETs are a source of citrullinated autoantigens and stim-
ulate inflammatory responses in rheumatoid arthritis. Sci Transl Med (2013)
5(178):178ra40. doi:10.1126/scitranslmed.3005580
7. Yoo DG, Floyd M, Winn M, Moskowitz SM, Rada B. NET formation induced
by Pseudomonas aeruginosa cystic fibrosis isolates measured as release of
myeloperoxidase-DNA and neutrophil elastase-DNA complexes. Immunol Lett
(2014) 160(2):186–94. doi:10.1016/j.imlet.2014.03.003
8. Leal SM Jr, Vareechon C, Cowden S, Cobb BA, Latge JP, Momany M, et al. Fun-
gal antioxidant pathways promote survival against neutrophils during infection.
J Clin Invest (2012) 122(7):2482–98. doi:10.1172/JCI63239
9. Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al.
Impairment of neutrophil extracellular trap degradation is associated with lupus
nephritis. Proc Natl Acad Sci U S A (2010) 107(21):9813–8. doi:10.1073/pnas.
0909927107
10. Leffler J, Gullstrand B, Jonsen A, Nilsson JA, Martin M, Blom AM, et al.
Degradation of neutrophil extracellular traps co-varies with disease activity in
patients with systemic lupus erythematosus. Arthritis Res Ther (2013) 15(4):R84.
doi:10.1186/ar4264
11. Papayannopoulos V, Staab D, Zychlinsky A. Neutrophil elastase enhances spu-
tum solubilization in cystic fibrosis patients receiving DNase therapy. PLoS One
(2011) 6(12):e28526. doi:10.1371/journal.pone.0028526
www.frontiersin.org August 2014 | Volume 5 | Article 378 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rahman and Gadjeva NETs and cystic fibrosis
12. Chen K, Nishi H, Travers R, Tsuboi N, Martinod K, Wagner DD, et al. Endocyto-
sis of soluble immune complexes leads to their clearance by FcgammaRIIIB but
induces neutrophil extracellular traps via FcgammaRIIA in vivo. Blood (2012)
120(22):4421–31. doi:10.1182/blood-2011-12-401133
13. Kochi Y, Suzuki A, Yamada R, Yamamoto K. Genetics of rheumatoid arthritis:
underlying evidence of ethnic differences. J Autoimmun (2009) 32(3–4):158–62.
doi:10.1016/j.jaut.2009.02.020
14. Rohrbach AS, Hemmers S, Arandjelovic S, Corr M, Mowen KA. PAD4 is not
essential for disease in the K/BxN murine autoantibody-mediated model of
arthritis. Arthritis Res Ther (2012) 14(3):R104. doi:10.1186/ar3829
15. Wang Y, Wysocka J, Sayegh J, Lee YH, Perlin JR, Leonelli L, et al. Human PAD4
regulates histone arginine methylation levels via demethylimination. Science
(2004) 306(5694):279–83. doi:10.1126/science.1101400
16. Wang Y, Li M, Stadler S, Correll S, Li P, Wang D, et al. Histone hypercitrulli-
nation mediates chromatin decondensation and neutrophil extracellular trap
formation. J Cell Biol (2009) 184(2):205–13. doi:10.1083/jcb.200806072
17. Neeli I, Khan SN, Radic M. Histone deimination as a response to inflamma-
tory stimuli in neutrophils. J Immunol (2008) 180(3):1895–902. doi:10.4049/
jimmunol.180.3.1895
18. Darrah E, Giles JT, Ols ML, Bull HG, Andrade F, Rosen A. Erosive rheumatoid
arthritis is associated with antibodies that activate PAD4 by increasing calcium
sensitivity. Sci Transl Med (2013) 5(186):186ra65. doi:10.1126/scitranslmed.
3005370
19. Inoue T, Suzuki Y, Yoshimaru T, Ra C. Reactive oxygen species produced up- or
downstream of calcium influx regulate proinflammatory mediator release from
mast cells: role of NADPH oxidase and mitochondria. Biochim Biophys Acta
(2008) 1783(5):789–802. doi:10.1016/j.bbamcr.2007.12.004
20. Yousefi S, Mihalache C, Kozlowski E, Schmid I, Simon HU. Viable neutrophils
release mitochondrial DNA to form neutrophil extracellular traps. Cell Death
Differ (2009) 16(11):1438–44. doi:10.1038/cdd.2009.96
21. Pilsczek FH, Salina D, Poon KK, Fahey C, Yipp BG, Sibley CD, et al. A
novel mechanism of rapid nuclear neutrophil extracellular trap formation
in response to Staphylococcus aureus. J Immunol (2010) 185(12):7413–25.
doi:10.4049/jimmunol.1000675
22. McInturff AM, Cody MJ, Elliott EA, Glenn JW, Rowley JW, Rondina MT,
et al. Mammalian target of rapamycin regulates neutrophil extracellular trap
formation via induction of hypoxia-inducible factor 1 alpha. Blood (2012)
120(15):3118–25. doi:10.1182/blood-2012-01-405993
23. Remijsen Q, Vanden Berghe T, Wirawan E, Asselbergh B, Parthoens E, De Rycke
R, et al. Neutrophil extracellular trap cell death requires both autophagy and
superoxide generation. Cell Res (2011) 21(2):290–304. doi:10.1038/cr.2010.150
24. Wang Y, Li P, Wang S, Hu J, Chen XA, Wu J, et al. Anticancer peptidylarginine
deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian
target of rapamycin complex 1 activity. J Biol Chem (2012) 287(31):25941–53.
doi:10.1074/jbc.M112.375725
25. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell (2008)
132(1):27–42. doi:10.1016/j.cell.2007.12.018
26. Tristan C, Shahani N, Sedlak TW, Sawa A. The diverse functions of GAPDH:
views from different subcellular compartments. Cell Signal (2011) 23(2):317–23.
doi:10.1016/j.cellsig.2010.08.003
27. Fialkow L, Wang Y, Downey GP. Reactive oxygen and nitrogen species as sig-
naling molecules regulating neutrophil function. Free Radic Biol Med (2007)
42(2):153–64. doi:10.1016/j.freeradbiomed.2006.09.030
28. Brandt T, Breitenstein S, von der Hardt H, Tummler B. DNA concentration and
length in sputum of patients with cystic fibrosis during inhalation with recom-
binant human DNase. Thorax (1995) 50(8):880–2. doi:10.1136/thx.50.8.880
29. Dubois AV, Gauthier A, Brea D, Varaigne F, Diot P, Gauthier F, et al. Influ-
ence of DNA on the activities and inhibition of neutrophil serine pro-
teases in cystic fibrosis sputum. Am J Respir Cell Mol Biol (2012) 47(1):80–6.
doi:10.1165/rcmb.2011-0380OC
30. Lorin MI, Gaerlan PF, Mandel ID, Denning CR. Composition of nasal secretion
in patients with cystic fibrosis. J Lab Clin Med (1976) 88(1):114–7.
31. Patrauchan MA, Sarkisova SA, Franklin MJ. Strain-specific proteome responses
of Pseudomonas aeruginosa to biofilm-associated growth and to calcium. Micro-
biology (2007) 153(Pt 11):3838–51. doi:10.1099/mic.0.2007/010371-0
32. Pier GB, Grout M, Zaidi TS, Olsen JC, Johnson LG, Yankaskas JR, et al. Role of
mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections.
Science (1996) 271(5245):64–7. doi:10.1126/science.271.5245.64
33. Young RL, Malcolm KC, Kret JE, Caceres SM, Poch KR, Nichols DP, et al. Neu-
trophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa:
evidence of acquired resistance within the CF airway, independent of CFTR.
PLoS One (2011) 6(9):e23637. doi:10.1371/journal.pone.0023637
34. Rada B, Leto TL. Pyocyanin effects on respiratory epithelium: relevance
in Pseudomonas aeruginosa airway infections. Trends Microbiol (2013)
21(2):73–81. doi:10.1016/j.tim.2012.10.004
35. Limoli DH, Rockel AB, Host KM, Jha A, Kopp BT, Hollis T, et al. Cationic
antimicrobial peptides promote microbial mutagenesis and pathoadaptation in
chronic infections. PLoS Pathog (2014) 10(4):e1004083. doi:10.1371/journal.
ppat.1004083
36. Konstan MW, Wagener JS, Pasta DJ, Millar SJ, Jacobs JR, Yegin A, et al. Clinical
use of dornase alpha is associated with a slower rate of FEV1 decline in cystic
fibrosis. Pediatr Pulmonol (2011) 46(6):545–53. doi:10.1002/ppul.21388
37. Khatua B, Bhattacharya K, Mandal C. Sialoglycoproteins adsorbed by
Pseudomonas aeruginosa facilitate their survival by impeding neutrophil extra-
cellular trap through siglec-9. J Leukoc Biol (2012) 91(4):641–55. doi:10.1189/
jlb.0511260
38. Schauer C, Janko C, Munoz LE, Zhao Y, Kienhofer D, Frey B, et al. Aggregated
neutrophil extracellular traps limit inflammation by degrading cytokines and
chemokines. Nat Med (2014) 20(5):511–7. doi:10.1038/nm.3547
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest
Received: 29 May 2014; accepted: 24 July 2014; published online: 11 August 2014.
Citation: Rahman S and Gadjeva M (2014) Does NETosis contribute to
the bacterial pathoadaptation in cystic fibrosis? Front. Immunol. 5:378. doi:
10.3389/fimmu.2014.00378
This article was submitted to Molecular Innate Immunity, a section of the journal
Frontiers in Immunology.
Copyright © 2014 Rahman and Gadjeva. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Immunology | Molecular Innate Immunity August 2014 | Volume 5 | Article 378 | 6
